Kymab investigational site 4401

Sutton

0 studies enrolling now · 1 studies all time

What they study most

Advanced Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer

Studies at this site

• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies — Stopped early